Stem cells of fallopian tube mucosa lost their stemness characteristics under prolonged conditions.
Indumathi S., Dhanasekaran M., Pankaj K., Sireesha G., Nilaja B., Nishant V.
Laboratory Study, published in JBRA Assist Reprod (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- JBRA Assist Reprod (2022)
- Country
- Brazil
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35238504
- DOI
- 10.5935/1518-0557.20210097
Abstract (original English)
Stem cells have been identified from various adult sources, including bone marrow, adipose tissue, and placenta, to name a few. Recently, the fallopian tube has also been identified as a novel source of therapeutics. However, the ability of stem cells from the fallopian tube mucosa to retain prolonged efficacy of proliferation and differentiation is yet to be explored. This forms the basis of the present study. Stem cells isolated from the fallopian tube mucosa were tested for their marker characterization (markers of mesenchymal, pericyte, epithelial, and cell adhesion molecules) at various passages (P1, P3, P5, P10, P15). Proliferation, differentiation (osteoblast and adipocytes), and karyotyping were also carried out at both early (P3) and late (P15) passages. Fallopian tube mucosa possesses mesenchymal stem cells, but they do not retain the ability to proliferate and differentiate beyond P15. Although fallopian tube mucosal MSCs (FT-MMSCs) possess stem cell attributes, they cannot outweigh or be used in parallel to existing stem cell sources due to their inability to retain stemness characteristics beyond P15. Since FT-MMSC studies are in their infancy, further in-depth research is warranted to test whether FT-MMSCs have a use in bench to bedside applications. FT-MMSCs might be linked to tubal inflammation and fallopian tube hyperplasia, which contributes to a possible role
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.